Banaschewski, T, Coghill, D, Santosh, P, Zuddas, A, Asherson, P, Buitelaar, J, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry
2006; 15: 476–95.
Greenhill, L, Kollins, S, Abikoff, H, McCracken, J, Riddle, M, Swanson, J, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry
2006; 45: 1284–93.
Prasad, V, Brogan, E, Mulvaney, C, Grainge, M, Stanton, W, Sayal, K. How effective are drug treatments for children with ADHD at improving on-task behaviour and academic achievement in the school classroom? A systematic review and meta-analysis. Eur Child Adolesc Psychiatry
2013; 22: 203–16.
Loe, IM, Feldman, HM. Academic and educational outcomes of children with ADHD. J Pediatr Psychol
2007; 32: 643–54.
Lichtenstein, P, Larsson, H. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med
2013; 368: 776.
van de Loo-Neus, GH, Rommelse, N, Buitelaar, JK. To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended?
2011; 21: 584–99.
Molina, BS, Hinshaw, SP, Eugene Arnold, L, Swanson, JM, Pelham, WE, Hechtman, L, et al. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry
2013; 52: 250–63.
Cortese, S, Holtmann, M, Banaschewski, T, Buitelaar, J, Coghill, D, Danckaerts, M, et al. European ADHD Guidelines Group. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry
2013; 54: 227–46.
Food and Drug Administration. FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Young Adults. FDA, 2011 (http://www.fda.gov/drugs/drugsafety/ucm277770.html).
Rey, JM, Sawyer, MG. Are psychostimulant drugs being used appropriately to treat child and adolescent disorders?
Br J Psychiatry
2003; 182: 284–6.
National Institute for Health and Care Excellence. Attention Deficit Hyperactivity Disorder. Diagnosis and Management of ADHD in Children, Young People and Adults. NICE clinical guideline 72. NICE, 2008.
Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management, Wolraich, M, Brown, L, Brown, RT, DuPaul, G, Earls, M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics
2011; 128: 1007–22.
Scheffler, RM, Hinshaw, SP, Modrek, S, Levine, P. The global market for ADHD medications. Health Aff (Millwood)
2007; 26: 450–7.
Zuvekas, SH, Vitiello, B. Stimulant medication use in children: a 12-year perspective. Am J Psychiatry
2012; 169: 160–6.
Olfson, M, Gameroff, MJ, Marcus, SC, Jensen, PS. National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry
2003; 160: 1071–7.
Sonuga-Barke, EJ, Brandeis, D, Cortese, S, Daley, D, Ferrin, M, Holtmann, M, et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry
2013; 170: 275–89.
Singh, I. Beyond polemics: science and ethics of ADHD. Nat Rev Neurosci
2008; 9: 957–64.
Graham, J, Coghill, D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs
2008; 22: 213–37.
Leslie, LK, Wolraich, ML. ADHD service use patterns in youth. J Pediatr Psychol
2007; 32: 695–710.
Bird, HR, Shrout, PE, Duarte, CS, Shen, S, Bauermeister, JJ, Canino, G. Longitudinal mental health service and medication use for ADHD among Puerto Rican youth in two contexts. J Am Acad Child Adolesc Psychiatry
2008; 47: 879–89.
Hjern, A, Weitoft, GR, Lindblad, F. Social adversity predicts ADHD-medication in school children–a national cohort study. Acta Paediatr
2010; 99: 920–4.
Lindblad, F, Ringbäck Weitoft, G, Hjern, A. Maternal and paternal psychopathology increases risk of offspring ADHD equally. Epidemiol Psychiatr Sci
2011; 20: 367–72.
Miller, AR, Kohen, D, Johnston, C. Child characteristics and receipt of stimulant medications: a population-based study. Ambul Pediatr
2008; 8: 175–81.
Romano, E, Thornhill, S, Lacourse, E. An 8-year follow-up study of profiles and predictors of methylphenidate use in a nationwide sample of boys. J Pediatr
2009; 155: 721–27.
Winterstein, AG, Gerhard, T, Shuster, J, Zito, J, Johnson, M, Liu, H, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother
2008; 42: 24–31.
Statistics Canada. Overview of Survey Instruments for 1994–1995 Data Collection, Cycle 1. Statistics Canada, 1995.
Achenbach, TM. Child Behavior Checklist. Department of Psychiatry, University of Vermont, 1991.
Boyle, MH, Offord, DR, Racine, Y, Sanford, M, Szatmari, P, Fleming, JE. Evaluation of the original Ontario Child Health Study scales. Can J Psychiatry
1993; 38: 397–405.
Tremblay, RE, Desmarais-Gervais, L, Gagnon, C, Charlebois, P. The Preschool Behavior Questionnaire: stability of its factor structure between cultures, sexes, ages and socioeconomic classes. Int J Behav Dev
1987; 10: 467–84.
Boivin, M, Pérusse, D, Dionne, G, Saysset, V, Zoccolillo, M, Tarabulsy, GM, et al. The genetic-environmental etiology of parents' perceptions and self-assessed behaviours toward their 5-month-old infants in a large twin and singleton sample. J Child Psychol Psychiatry
2005; 46: 612–30.
Radloff, LS. The CESD-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas
1977; 1: 385–401.
Rucklidge, JJ. Gender differences in attention-deficit/hyperactivity disorder. Psychiatr Clin North Am
2010; 33: 357–73.
Galéra, C, Côté, SM, Bouvard, MP, Pingault, JB, Melchior, M, Michel, G, et al. Early risk factors for hyperactivity-impulsivity and inattention trajectories from age 17 months to 8 years. Arch Gen Psychiatry
2011; 68: 1267–75.
Sonuga-Barke, EJ, Halperin, JM. Developmental phenotypes and causal pathways in attention deficit/hyperactivity disorder: potential targets for early intervention?
J Child Psychol Psychiatry
2010; 51: 368–89.
Singh, I. Doing their jobs: mothering with Ritalin in a culture of mother-blame. Soc Sci Med
2004; 59: 1193–205.
Singh, GK, Yu, SM, Kogan, MD. Health, chronic conditions, and behavioral risk disparities among U.S. immigrant children and adolescents. Public Health Rep
2013; 128: 463–79.
Knopf, H, Holling, H, Huss, M, Schlack, R. Prevalence, determinants and spectrum of attention-deficit hyperactivity disorder (ADHD) medication of children and adolescents in Germany: results of the German Health Interview and Examination Survey (KiGGS). BMJ Open
2012; 2: e000477.
Visser, SN, Lesesne, CA, Perou, R. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics
2007; 119 (suppl 1): S99–106.
Pastor, PN, Reuben, CA. Racial and ethnic differences in ADHD and LD in young school-age children: parental reports in the National Health Interview Survey. Public Health Rep
2005; 120: 383–92.
Zima, BT, Bussing, R, Tang, L, Zhang, L, Ettner, S, Belin, TR, et al. Quality of care for childhood attention-deficit/hyperactivity disorder in a managed care Medicaid program. J Am Acad Child Adolesc Psychiatry
2010; 49: 1225–37.
Thomas, R, Mitchell, GK, Batstra, L. Attention-deficit/hyperactivity disorder: are we helping or harming?
2013; 347: f6172.
Boisjoli, R, Vitaro, F, Lacourse, É, Barker, ED, Tremblay, RE. Impact and clinical significance of a preventive intervention for disruptive boys: a 15 year follow-up. Br J Psychiatry
2007; 191: 415–9.